Loading company…
Cambridge-based biotech using mRNA technology to develop vaccines and therapeutics, including the COVID-19 vaccine Spikevax.
Founded in 2010 and based in Cambridge, US, Moderna, Inc. develops mRNA-based vaccines and therapeutics, including the FDA-approved COVID-19 vaccine Spikevax and vaccines for influenza and RSV. It received a grant of USD 472.00 mn from the Biomedical Advanced Research and Development Authority and raised USD 604.3 mn through an IPO in December 2018. In fiscal 2024 it reported revenue of USD 3,236.00 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in